title: Facilitating the safe use of insulin pens in hospitals through a mentored quality-improvement program.
abstract: OBJECTIVE
  Results of the MENTORED QUALITY IMPROVEMENT IMPACT PROGRAM℠ (MQIIP) on Ensuring Insulin Pen Safety in Hospitals, which was part of an ASHP educational initiative aimed at ensuring the safe use of insulin pens in hospitals, are described.
  
  
  METHODS
  During this ASHP initiative, which also included continuing-education activities and Web-based resources, distance mentoring by pharmacists with expertise in the safe use of insulin pens was provided to interprofessional teams at 14 hospitals between September 2014 and May 2015. The results of baseline assessments of nursing staff knowledge of insulin pen use, insulin pen storage and labeling audits, and insulin pen injection observations conducted in September and October 2014 were the basis for insulin pen quality-improvement plans. Postintervention data were collected in April and May 2015.
  
  
  RESULTS
  Compared with the baseline period, significant improvements in nurses' knowledge of insulin pen use, insulin pen labeling and storage, and insulin pen administration were observed in the postintervention period despite the relatively short time frame for implementation of quality-improvement plans. Program participants are committed to sustaining and building on improvements achieved during the program. The outcome measures described in this report could be adapted by other health systems to identify opportunities to improve the safety of insulin pen use.
  
  
  CONCLUSIONS
  Focused attention on insulin pen safety through an interprofessional team approach during the MQIIP enabled participating sites to detect potential safety issues based on collected data, develop targeted process changes, document improvements, and identify areas requiring further intervention. A sustained organizational commitment is required to ensure the safe use of insulin pen devices in hospitals.
authors.affiliation: William Beaumont Hospital, Royal Oak, MI. mark.lutz@beaumont.org.
authors.forename: Mark F
authors.initials: MF
authors.lastname: Lutz
authors.affiliation: University of Mississippi School of Pharmacy, Jackson, MS.
authors.forename: Stuart T
authors.initials: ST
authors.lastname: Haines
authors.affiliation: NewYork-Presbyterian Hospital, New York, NY.
authors.forename: Christine A
authors.initials: CA
authors.lastname: Lesch
authors.affiliation: Brigham and Women's Hospital, Boston, MA.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Szumita
mesh_terms: D004348:Drug Labeling / Q000592:standards / Q000639:trends; D004356:Drug Storage / Q000592:standards; D006761:Hospitals / Q000592:standards* / Q000639:trends; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007267:Injections; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D007332:Insulin Infusion Systems; D008611:Mentors / Q000193:education; D024802:Nurse's Role; D058996:Quality Improvement / Q000592:standards* / Q000639:trends; D011795:Surveys and Questionnaires
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin